Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
HOOCCH2CH2COCOONa
CAS Number:
Molecular Weight:
168.08
UNSPSC Code:
12352204
NACRES:
NA.32
PubChem Substance ID:
EC Number:
244-836-6
Beilstein/REAXYS Number:
4597521
MDL number:
product line
BioUltra
Quality Level
assay
≥98% (perchloric acid titration)
form
powder
impurities
≤0.0005% Phosphorus (P), ≤0.1% Insoluble matter
solubility
H2O: 0.5 M, clear, colorless
anion traces
chloride (Cl-): ≤0.05%, sulfate (SO42-): ≤0.05%
cation traces
Al: ≤0.0005%, Ca: ≤0.001%, Cu: ≤0.0005%, Fe: ≤0.0005%, K: ≤0.005%, Mg: ≤0.0005%, NH4+: ≤0.05%, Pb: ≤0.001%, Zn: ≤0.0005%
storage temp.
2-8°C
SMILES string
[Na+].OC(=O)CCC(=O)C([O-])=O
InChI
1S/C5H6O5.Na/c6-3(5(9)10)1-2-4(7)8;/h1-2H2,(H,7,8)(H,9,10);/q;+1/p-1
InChI key
MOTOGHHLNTXPTI-UHFFFAOYSA-M
Application
α-Ketoglutaric acid sodium salt has been used in the human kynurenine amino transferase II (KAT II) inhibition spectra assay.
Biochem/physiol Actions
α-Ketoglutaric acid is the precursor for L-glutamic acid.
α-Ketoglutaric acid is a key intermediate in the TCA Cycle. It also plays an important role in preventing nitrogen overload by combining with nitrogen released within the cell.
Still not finding the right product?
Explore all of our products under α-Ketoglutaric acid sodium salt
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Structure-based design of irreversible human KAT II inhibitors: Discovery of new potency-enhancing interactions
Tuttle JB, et al.
ACS Medicinal Chemistry Letters, 4(1), 37-40 (2012)
Amino Acids in Therapy: A Guide to the Therapeutic Application of Protein Constituents, 34-34 (1985)
Piotr Dobrowolski et al.
Nutrition (Burbank, Los Angeles County, Calif.), 29(3), 556-561 (2012-12-12)
Proton-pump inhibitors, such as omeprazole, are widely used in the prevention and treatment of gastroesophageal diseases. However, an association between proton-pump inhibitors and the increased risk of bone fractures has been observed, especially in patients treated for extended periods. Conversely